The financing was led by OrbiMed Advisors, a leading investment firm focused on the healthcare sector, alongside additional investors including Frazier Healthcare Partners and Alpine BioVentures. Alpine BioVentures
Merck and Pfizer are co-developing and co-commercializing ertugliflozin under their global collaboration agreement, signed in April 2013. Patients treated with either of two doses, 5 mg or 15mg,
The organizations aim to build a first-of-its-kind diabetes advisor for patients and caregivers. As part of their commitment to the diabetes community, the organizations also announced a challenge
The facility is scheduled to be operational in September 2016, and will be FDA registered and compliant with Good Manufacturing Practice standards. Spotlight Innovation will also use the
AG-348 is wholly owned by Agios. Data will be presented today at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
It is estimated that as many as six million children and adults may be affected by primary immunodeficiencies (PI) worldwide.1 With the addition of Cuvitru following the completion
The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise
TD-1473 is specifically designed to penetrate the intestinal wall and act directly at the site of inflammation with minimal systemic exposure. Data from the study demonstrated TD-1473 to
The transaction is conditioned on the close of sufficient financing to fund the operations of the combined company, and due diligence review. FPMI intends to execute the transaction
The sNDA for the 72 mcg dose of linaclotide is based on efficacy and safety data from a double-blind, placebo-controlled Phase III clinical trial of 1,223 adult patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.